Abstract
Adenovirus-mediated cytotoxic gene therapy for prostate cancer offers a new therapeutic modality. Currently, intraprostatic injection is used to target vectors to the prostate. Transcriptional targeting of genes under the control of prostate-speci®c promoters had been shown to be speci®c, but is limited by a low expression. Increasing the transduction of the vector (Adv) into the cell might increase the expression of therapeutic genes. The adenovirus uses the Coxsackie adenoviral receptor (CAR) to adhere to the cell membrane by means of its viral knob, after which internalisation occurs under the in uence of integrins. Many tumour cells have limited or absent CAR. We have evaluated the possibility of retargeting adenoviral vectors towards the pantumoral EpCAM antigen and the ®broblast growth factor receptor (FGFR) in order to increase transduction in vitro.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
